<DOC>
	<DOCNO>NCT00934362</DOCNO>
	<brief_summary>Mucus clearance impair cystic fibrosis . Inhaled surfactant may reduce adhesive force mucus airway surface improve mucus clearance . This turn improve lung health . The investigator propose measure mucus clearance lucinactant vehicle administration patient cystic fibrosis .</brief_summary>
	<brief_title>Effect Lucinactant Mucus Clearance Cystic Fibrosis Lung Disease</brief_title>
	<detailed_description>This single-center pilot study design double-blind , randomize , cross-over clinical trial evaluate effect inhale lucinactant , investigational peptide-containing synthetic surfactant ( 6 ml 20 mg total phospholipid ( TPL ) /mL solution x 5 dos ) patient mild moderate CF lung disease . Lucinactant vehicle deliver via 510k approve vibrate mesh nebulizer , Pari eFlowTM . The study duration correspond 2-10 day screen phase , follow 20 day post-randomization phase consist two treatment period ( 3 day ) washout period ( 14 day ) . A total 16 patient enrol randomly assign one two treatment sequence ( Lucinactant follow vehicle vehicle follow lucinactant ) . The primary outcome rate MC , assess via gamma scintigraphy , post-lucinactant post vehicle . Secondary outcome include rate cough clearance ( CC ) , lung clearance index ( LCI ) , absolute change baseline FEV1 5 dos study medication , CF-specific quality life score ( via CFQ-R instrument ) , vitro assessment sputum rheology , various safety parameter .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<criteria>Cystic fibrosis FEV1 &gt; 40 % Unstable lung disease Unable unwilling stop hypertonic saline dornase alfa 3 day prior study period Relevant drug allergy intolerance Recent investigational drug use ( 30 day )</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>